BioCryst Pharmaceuticals is facing a patent infringement lawsuit concerning its hereditary angioedema (HAE) drug, Orladeyo [1]. The lawsuit was filed by Kalbior Pharmaceuticals, which claims that BioCryst's Orladeyo infringes on Kalbior's patents related to its own HAE drug, Takhzyro [1].
When Could Orladeyo's Patents Expire?
The patent landscape for Orladeyo is complex and includes multiple patents. DrugPatentWatch.com indicates that patents related to Orladeyo are set to expire at various times, with some as early as 2026, and others extending further into the future [2]. These expiration dates are crucial for understanding potential market entry for generics or biosimilars.
What Are the Specific Allegations in the Lawsuit?
Kalbior Pharmaceuticals alleges that BioCryst's Orladeyo infringes on its U.S. Patent No. 10,947,101 and other related patents [1]. The core of the dispute appears to center on the method of treating HAE, with Kalbior asserting that Orladeyo's therapeutic approach falls within the scope of its patented inventions [1].
How Does Orladeyo Work?
Orladeyo (berotralstat) is an oral kallikrein inhibitor that works by targeting and inhibiting the plasma kallikrein enzyme [3]. This enzyme plays a role in the cascade that leads to HAE attacks. By blocking plasma kallikrein, Orladeyo aims to reduce the frequency of HAE attacks [3].
What is Hereditary Angioedema (HAE)?
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, unpredictable swelling attacks, often affecting the face, abdomen, and limbs [4]. These attacks can be painful and debilitating, and in some cases, can be life-threatening if they involve the airway [4].
Who Else is Involved in the HAE Treatment Market?
The HAE market includes several other therapeutic options, such as Takhzyro (lanadelumab-flyo), which is also developed by Kalbior Pharmaceuticals and is an injectable monoclonal antibody targeting plasma kallikrein [1][5]. Other treatments for HAE include CGRP inhibitors and androgens, each with different mechanisms of action and administration routes [4].
What Are the Potential Impacts of This Lawsuit?
The outcome of the patent infringement lawsuit could have significant implications for both BioCryst Pharmaceuticals and Kalbior Pharmaceuticals. If Kalbior is successful, it could lead to injunctions preventing the sale of Orladeyo, or substantial financial penalties for BioCryst [1]. Conversely, if BioCryst prevails, it would protect its market position for Orladeyo. The lawsuit also highlights the competitive nature of the HAE drug market and the importance of intellectual property in pharmaceutical development.
Cited Sources
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. BioCryst Pharmaceuticals. Orladeyo (berotralstat).
4. National Organization for Rare Disorders (NORD). Hereditary Angioedema.
5. Takeda Pharmaceutical Company. Takhzyro (lanadelumab-flyo).